Медицинская литература. Новинки

 

 

 

 

 

 

Влияние субклинического тиреотоксикоза на сердечно-сосудистую систему

Вы можете загрузить полный текст статьи в формате pdf

ГБОУ ДПО “Российская медицинская академия последипломного образования” Минздрава России, Москва Субклинический тиреотоксикоз характеризуется сниженным или неопределяемым уровнем тиреотропного гормона в сочетании с нормальными уровнями тироксина и трийодтиронина. Клинические проявления субклинического тиреотоксикоза являются малоизученными. Субклинический тиреотоксикоз оказывает несколько эффектов на сердечно-сосудистую систему, например, увеличение частоты сердечных сокращений, массы левого желудочка. Экспериментальные исследования выявили связь между субклиническим тиреотоксикозом и ишемической болезнью сердца, частотой возникновения фибрилляции предсердий и сердечной дисфункции.

Ключевые слова:
субклинический тиреотоксикоз, сердечно-сосудистая система, частота сердечных сокращений, фибрилляция предсердий, масса миокарда левого желудочка, subclinical hyperthyroidism, cardiovascular system, heart rate, atrial fibrillation, left ventricular mass

Литература:
1.Canaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The Colorado Thyroid Disease Prevalence Study. // Arch. Intern. Med. 2000; 160(4):526. doi: 10.1001/archinte.160.4.526.
2.Hollowell J.G., Staehling N.W., Flanders W.D., et al. Serum TSH, T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). // J ClinEndocrinol Metab. 2002;87(2):489-499. doi: 10.1210/jcem.87.2.8182
3.Sawin C.T., Geller A., Wolf P.A., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. // N Engl J Med. 1994;331(19):1249-1252. doi: 10.1056/nejm199411103311901.
4.Gharib H., Tuttle R.M., Baskin H.J., et al. Subclinical thyroid dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. // Endocr Pract. 2004;10(6):497-501. doi: 10.4158/ep.10.6.497.
5.Surks M.I., Ortiz E., Daniels G.H., et al. Subclinical thyroid disease. // JAMA. 2004;291(2):228. doi: 10.1001/jama.291.2.228.
6.Wilson G.R., Curry R.W. Subclinical thyroid disease. // Amer Fam Physician. 2005;72(8):1517-1524.
7.Дедов И.И., Мельниченко Г.А. Болезнь Грейвса и эндокринная офтальмопатия. - М.; 2012.
8.Cooper D.S. Approach to the patient with subclinical hyperthyroidism. // J Clin Endocrinol Metab. 2007;92(1):3-9. doi: 10.1210/jc.2006-2472.
9.Biondi B., Palmieri E.A., Klain M., et al. Subclinical hyperthyroidism: clinical features and treatment options. // Eur J Endocrinol / European Federation of Endocrine Societies. 2005;152(1):1-9. doi: 10.1530/eje.1.01809.
10.Ross D.S. Subclinical thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott, Williams and Wilkins; 2000; 1016-1020.
11.Papi G., Pearce E.N., Braverman L.E., et al. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. // Am J Med. 2005;118(4):349-361. doi: 10.1016/j.amjmed.2005.01.004.
12.Cooper D.S. Hyperthyroidism. // The Lancet. 2003;362(9382):459-468. doi: 10.1016/s0140-6736(03)14073-1.
13.Toft A.D. Subclinical hyperthyroidism. // N Engl J Med. 2001;345(7): 512-516. doi: 10.1056/NEJMcp010145.
14.Boelaert K. Thyroid hormone in health and disease. // J Endocrinol. 2005;187(1):1-15. doi: 10.1677/joe.1.06131.
15.Brownlie B.E.W., Legge H.M. Thyrotropin results in euthyroid patients with a past history of hyperthyroidism. // Eur J Endocrinol / European Federation of Endocrine Societies. 1990;122(5):623-627. doi: 10.1530/acta.0.1220623.
16.Charkes N.D. The many causes of subclinical hyperthyroidism. // Thyroid. 1996;6(5):391-396. doi: 10.1089/thy.1996.6.391.
17.Faber J., Galloe A.M. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. // Eur J Endocrinol / European Federation of Endocrine Societies. 1994;130(4):350-356. doi: 10.1530/eje.0.1300350.
18.Marqusee E., Haden S.T., Utiger R.D. Subclinical thyrotoxicosis. // Endocrinol Metab Clin N Am. 1998;27(1):37-49. doi: 10.1016/s0889-8529(05)70296-6.
19.Sawin C.T. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. // Arch Intern Med. 1991;151(1):165. doi: 10.1001/archinte.1991.00400010159025.
20.Cooper D.S. Subclinical thyroid disease: A clinician’s perspective. // Ann Intern Med. 1998;129(2):135. doi: 10.7326/0003-4819-129-2-199807150-00016.
21.Biondi B., Palmieri E.A., Fazio S., et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. // J Clin Endocrinol Metab. 2000;85(12):4701-4705. doi: 10.1210/jcem.85.12.7085.
22.Sgarbi J.A., Villaca F.G., Garbeline B., et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. // J Clin Endocrinol Metab. 2003;88(4):1672-1677. doi: 10.1210/jc.2002-021046.
23.Pearce E.N., Yang Q., Benjamin E.J., et al. Thyroid function and left ventricular structure and function in the Framingham Heart Study. // Thyroid. 2010;20(4):369-373. doi: 10.1089/thy.2009.0272.
24.Dorr M., Ittermann T., Aumann N., et al. Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle-aged and older subjects: results from a 5-year follow-up. // Clin Endocrinol (Oxf). 2010;73(6):821-826. doi: 10.1111/j.1365-2265.2010.03882.x.
25.Petretta M., Bonaduce D., Spinelli L., et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. // Eur J Endocrinol / European Federation of Endocrine Societies. 2001;145(6):691-696. doi: 10.1530/eje.0.1450691.
26.Yavuz H., Altunbag H., Balci M., et al. Normal systolic time intervals in subclinical hyperthyroidism. // J Endocrinol Invest. 2000; 23(7; SUPP 1):38-38.
27.Psaltopoulou T., Ilias I., Toumanidis S., et al. Endogenous subclinical hyperthyroidism: Metabolic and cardiac parameters. // Eur J Intern Med. 2007;18(5):423-429. doi: 10.1016/j.ejim.2006.12.010.
28.Leese G.P., Jung R.T., Guthrie C., et al. Morbidity in patients on l-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. // Clin Endocrinol (Oxf). 1992;37(6):500-503. doi: 10.1111/j.1365-2265.1992.tb01480.x.
29.Dorr M., Robinson D.M., Wallaschofski H., et al. Low serum thyrotropin is associated with high plasma fibrinogen. // J Clin Endocrinol Metab. 2006;91(2):530-534. doi: 10.1210/jc.2005-1786.
30.Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. // Clin Endocrinol (Oxf). 2006;64(3): 323-329. doi: 10.1111/j.1365-2265.2006.02464.x.
31.Franchini M., Lippi G., Targher G. Hyperthyroidism and venous thrombosis: A casual or causal association? A systematic literature review. // Clin Appl Thromb Hemost. 2010;17(4):387-392. doi: 10.1177/1076029610364521.
32.Volzke H., Robinson D.M., Schminke U., et al. Thyroid function and carotid wall thickness. // J Clin Endocrinol Metab. 2004;89(5): 2145-2149. doi: 10.1210/jc.2003-031028.
33.Dorr M., Empen K., Robinson D.M., et al. The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. // Eur J Endocrinol. 2008;159(2):145-152. doi: 10.1530/EJE-08-0140.
34.Tenerz A., Forberg R., Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? // J Intern Med. 2009;228(3):229-233. doi: 10.1111/j.1365-2796.1990.tb00223.x.
35.Machill K., Scholz G.H. Dependence of haemodynamic changes in hypothyroidism on age of patients and etiology hyperthyroidism. In: Braverman E, Eber O, Langsteger W, editors. Heart and thyroid. Wien; 1994. p. 203.
36.Polikar R., Feld G.K., Dittrich H.C., et al. Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. // J Am Coll Cardiol. 1989;14(4):999-1002. doi: 10.1016/0735-1097(89)90479-8.
37.Auer J., Scheibner P., Mische T., et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. // Am Heart J. 2001;142(5): 838-842. doi: 10.1067/mhj.2001.119370.
38.Gammage M.D. Association between serum free thyroxine concentration and atrial fibrillation. // Arch Intern Med. 2007;167(9):928. doi: 10.1001/archinte.167.9.928.
39.Surks M.I., Goswami G., Daniels G.H. The thyrotropin reference range should remain unchanged. // J Clin Endocrinol Metab. 2005;90(9):5489-5496. doi: 10.1210/jc.2005-0170.
40.Parle J.V., Maisonneuve P., Sheppard M.C., et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. // The Lancet. 2001;358(9285):861-865. doi: 10.1016/s0140-6736(01)06067-6.

Influence of subclinical hyperthyroidism on the cardiovascular system

Subclinical hyperthyroidism occurs when the serum TSH is below the lower limit of the reference range and the free T4 and T3 concentrations are normal. Тhe clinical significance of subclinical hyperthyroidism is much debated. Subclinical hyperthyroidism has been associated with several biological effects on cardiovascular system, such as increased heart rate, left ventricular mass. Observational studies have reported an association between subclinical hyperthyroidism and coronary heart disease, incident atrial fibrillation, and cardiac dysfunction.

Keywords:
субклинический тиреотоксикоз, сердечно-сосудистая система, частота сердечных сокращений, фибрилляция предсердий, масса миокарда левого желудочка, subclinical hyperthyroidism, cardiovascular system, heart rate, atrial fibrillation, left ventricular mass